Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 25–48 of 297
Avaí Bio–Austrianova’s longevity protein program enters production
Avaí Bio and Austrianova have begun GMP-compliant production of a Master Cell Bank for genetically modified cells engineered to overexpress α-Klotho, a protein associated with improved cognitive resilience and organ function in aging. This transition from research to scalable manufacturing represents a critical step toward clinical cell therapy delivery for age-related disease.
Klotho Longevity Therapy: Clinical Implementation and Biomarker Response
GARM Clinic conducted the inaugural Klotho Longevity Residency, administering a proprietary Klotho therapy via lipid nanoparticle platform to 22 participants and measuring individualized biomarker responses. The event represents a clinical implementation model that combines direct researcher-patient engagement with supervised biological intervention and biomarker tracking.
Alpha-Klotho Manufacturing Milestone Clears Path to Clinic
Avaí Bio has completed a Good Manufacturing Practice Master Cell Bank for alpha-Klotho therapy, establishing the standardized cellular foundation required for consistent clinical-scale production. This manufacturing milestone addresses a critical bottleneck in longevity biotechnology: translating promising discoveries into reliably produced treatments.
Peptide Compounding Approval: What Regulated Access Actually Permits
An FDA advisory committee voted to recommend six peptides for inclusion on the Section 503A Bulks List, a decision that would permit regulated compounding but not blanket commercial access. The vote exposes a fundamental mismatch between regulatory frameworks designed for discrete disease treatment and the preventive interventions emerging in longevity medicine.
Telomere Signaling Inhibition Restores Aging Immunity
Blocking telomeric DNA damage signaling through targeted inhibition of telomeric noncoding RNAs restores blood cell production and immune function in aged and telomerase-deficient mice, with comparable improvements observed in human hematopoietic stem cells. This finding identifies a specific molecular mechanism driving hematopoietic aging and suggests a therapeutic pathway for restoring immune competence in advanced age.
Senescent Cell Removal Plus Stem Cell Restoration Extends Lifespan 70%
Immorta Bio's AI-driven dual-target approach simultaneously addresses senescent cell accumulation and stem cell decline, demonstrating 70% mean and 80% median lifespan extension in preclinical models. The platform integrates personalized medicine with senolytic immunotherapy and cellular rejuvenation, suggesting a mechanistic approach to systemic longevity rather than single-pathway intervention.
Antioxidants selectively clear senescent muscle cells
Antioxidants can selectively eliminate senescent cells in muscle tissue by modulating mTOR signaling, restoring proper nutrient sensing that these aged cells have lost. This mechanism offers a targeted approach to removing dysfunctional cells without broad-spectrum intervention, with direct implications for maintaining muscle integrity and metabolic function in aging.
GARM expands gene therapy platform with Klotho
GARM Clinic has added Klotho to its non-permanent gene therapy platform alongside Follistatin and VEGF, positioning itself as a clinical destination for early-stage longevity interventions. Klotho addresses age-related decline in the protein's natural production, targeting mitochondrial function, metabolic resilience, and systemic health markers that degrade with age.
Reprogrammed Cardiomyocytes Soften the Blow in Heart Attack
Partial reprogramming of heart muscle cells using three Yamanaka factors (OCT4, SOX2, KLF4) enables cardiomyocytes to complete cell division after myocardial infarction in mice by dismantling their contractile scaffold without triggering uncontrolled proliferation. This approach addresses a fundamental barrier to cardiac regeneration: mature heart cells lose divisibility because their rigid internal structure prevents cytokinesis, even when DNA replication is initiated.
New peptide drugs on the horizon with PepLib–Lilly collab
Eli Lilly and PepLib Biotech have formed a collaboration to develop peptide-based therapeutics designed to target specific disease pathways with precision. Peptides represent a distinct therapeutic modality with applications in age-related conditions, metabolic dysfunction, and cardiovascular disease—key drivers of healthspan and lifespan limitations.
MDLifespan and Cenegenics expand toxin-clearing therapy
MDLifespan and Cenegenics are expanding access to Therapeutic Plasma Exchange (TPE), a procedure that removes environmental toxins, microplastics, and heavy metals from circulation to reduce chronic inflammation. The partnership positions toxin clearance as a foundational longevity strategy, addressing inflammation that undermines cognitive, metabolic, and cardiovascular function.
LifespanningRx launches partner program for peptide therapy
LifespanningRx introduced a Partner Program enabling non-clinical businesses to offer peptide therapy through clinician oversight, pharmacy fulfillment, and white-label infrastructure. This addresses a gap in scalable delivery of peptide-based interventions within the broader precision medicine ecosystem.
Decreased Glucose Metabolism and Declined Chaperones Are Unique Features Required for the Survival of Senescent Fibroblasts and Pyruvate Dehydrogenase Is a Potent Senolytic Target
Senescent fibroblasts depend on reduced glucose metabolism and maintained chaperone proteins for survival. Inhibiting pyruvate dehydrogenase selectively eliminates senescent cells, including therapy-induced senescent cancer cells, with synergistic enhancement when combined with chaperone inhibition.
Exosome Platform Enables Earlier Detection and Tissue Repair
Human Continuum secured $5.13 million in seed funding to advance exosome-based therapeutics and diagnostics for musculoskeletal repair and regeneration. The platform approach—combining investigational treatments for osteoarthritis with diagnostic tools and biomarker panels—addresses a significant clinical gap where current therapies emphasize symptom management over functional restoration.
Cellular Reprogramming Rescues Memory-Encoding Neurons
Partial cellular reprogramming using three Yamanaka factors (OSK) successfully restored memory function in aged mice and Alzheimer's disease models by rejuvenating memory-encoding neurons while preserving their neuronal identity. This approach demonstrates that targeted reprogramming of engram cells can reverse age-related cognitive decline without causing dedifferentiation or memory loss.
Klotho Therapy Gains Direct Researcher-Patient Dialogue Model
GARM Clinic convened three leading Klotho researchers with 22 participants receiving a Klotho-based intervention, creating direct dialogue between scientists and patients—a rare model in longevity medicine that reflects shifting expectations for transparency and engagement in therapeutic development.
FGF21 Gene Therapy Preserves Multi-Organ Function in Aged Mice
A single injection of AAV-delivered FGF21 gene therapy extended lifespan by over 20% in aged mice while preserving function across liver, kidneys, heart, skeletal muscle, and brain. The treatment improved metabolic health markers and activated adaptive programs that countered multiple aging mechanisms simultaneously, suggesting metabolic interventions may have broader relevance to systemic resilience.
Stem cell therapy might improve aging frailty
Stem cell therapy demonstrates potential to address frailty in aging by restoring cellular repair capacity and tissue regeneration. This approach targets a fundamental mechanism of aging decline rather than managing symptoms.
#387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field
Peptides represent a legitimate therapeutic class with demonstrated efficacy, but clinical validation is confined to a narrow subset of compounds. Most peptide applications currently marketed fall outside evidence-supported use, requiring practitioners to distinguish between established interventions and speculative applications.
Banked Bone Marrow Rebuilds Immune Function at Scale
Cryopreserved bone marrow banking from deceased donors enables scalable transplantation without matching delays, positioning hematopoietic stem cell therapy as infrastructure for addressing immunosenescence rather than a niche oncology tool. As immune aging drives chronic inflammation and tissue dysfunction, accessible cell banking could shift medicine from treating immune decline to rebuilding immune capacity systematically.
MuseCells outperform MSCs in age-related tissue regeneration
Dezawa MuseCells represent a rare stress-resistant stem cell subpopulation with regenerative capacity that appears to overcome limitations of conventional mesenchymal stem cells, which have underperformed clinically due to fundamental misunderstandings of their biological function. This distinction carries significant implications for regenerative medicine and tissue preservation across the aging process.
FGF21 Gene Therapy Extends Lifespan 20% in Aging Mice
Late-life delivery of FGF21 gene therapy via muscle targeting extended median lifespan in mice by 20.5% while improving metabolic health, mitochondrial function, and reducing age-related pathology across multiple organs. The intervention mimics metabolic benefits of exercise and caloric restriction without requiring sustained behavioral change.
Mesenchymal stem cell therapy targets cardiac and cognitive aging
Longeveron is advancing laromestrocel, an allogeneic mesenchymal stem cell therapy derived from young donor bone marrow, across four clinical indications including hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. The company's licensing strategy at BIO 2026 signals movement toward commercialization of a cellular therapy platform with demonstrated efficacy signals across multiple disease states.
Cellular Reprogramming: The Expert Roundup
Cellular reprogramming—the process of resetting aged cells to younger functional states through partial application of reprogramming factors—represents a fundamental shift in how aging is understood: not as irreversible damage accumulation, but as a modifiable biological state. Clinical trials are imminent, and the field has moved from theoretical elegance to therapeutic platform with potential applications across age-associated diseases.